Guangxi Medical University
76
4
7
19
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 50/100
7.9%
6 terminated/withdrawn out of 76 trials
76.0%
-10.5% vs industry average
26%
20 trials in Phase 3/4
0%
0 of 19 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (76)
Comparison of Partial Stomach-Partitioning and Conventional Gastrojejunostomy for the Treatment of Gastric Outlet Obstruction in Advanced Gastric Cancer
Role: lead
A Prospective Study of Cadonilimab in Hepatocellular Carcinoma After Radical Surgery With High Risk of Recurrence
Role: lead
Adjuvant TACE in HCC With High-risk Recurrence Factors
Role: lead
Conversion or Neoadjuvant Therapy in Hepatocellular Carcinoma
Role: lead
HAIC Sequential TAE Combined With Lenvatinib and Tislelizumab in Unresectable HCC
Role: lead
PD-1 Inhibitor Plus GP as Neoadjuvant Therapy for Locoregionally Advanced Nasopharyngeal Carcinoma
Role: lead
Induction Chemotherapy With Nab-paclitaxel, Cisplatin and Fluorouracil for Locoregionally Advanced Nasopharyngeal Carcinoma
Role: lead
The Workplace-Based Hypertension Management Program
Role: lead
Artificial Intelligence-assisted Diagnosis
Role: collaborator
A Prospective, Non-interventional Cohort Study of Subsolid Pulmonary Nodules
Role: collaborator
Adjuvant Immune Checkpoint Inhibitors in Postoperative Hepatocellular Carcinoma
Role: lead
Hearing Impairment of Nasopharyngeal Carcinoma
Role: lead
TACE Combined With Tyrosine Kinase Inhibitors and Tislelizumab in Unresectable Hepatocellular Carcinoma
Role: lead
Fruquintinib Plus SOX as Neoadjuvant Therapy for Locally Advanced Gastric Adenocarcinoma
Role: lead
Effect of Smoked Plum and Chewing Gum on Postoperative Bowel Function Following Hepatic Resection
Role: lead
Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC
Role: lead
Adjuvant Tislelizumab Plus Lenvatinib for Patients at High-risk of HCC Recurrence After Curative Resection or Ablation
Role: lead
Aprepitant Plus Granisetron and Dexamethasone for the Prevention of Vomiting in Patients With HAIC Therapy for HCC
Role: lead
Adjuvant Entecavir or Tenofovir for Postoperative HBV-HCC
Role: lead
Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi
Role: lead